Program
olutasidenib
Also written as “Olutasidenib”, “Olutasidenib + TMZ” and “FT-2102 (olutasidenib)”.
Its studies are mostly in Leukemia, Myeloid, Acute · Glioma · Glioblastoma, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 20 open or running | phase 2since Mar 21, 2016 | Mar 21, 2016 | none ahead |
| Rigel Pharmaceuticals | 22 open or running | phase 4since Mar 12, 2026 | Nov 22, 2023 | Apr 30, 2027phase 4 · NCT07486713 |
| Kissei Pharmaceutical | 11 open or running | phase 2since May 18, 2026 | May 18, 2026 | Sep 2030phase 2 · NCT07604064 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 21, 2016First study: phase 2 study in Leukemia, Myeloid, AcuteNew to Novo NordiskNovo Nordisk · NCT02719574 · 336 enrolled · United States, Australia, Canada and more
- Sep 17, 2018Phase 2 study in GlioblastomaNovo Nordisk · NCT03684811 · 93 enrolled · United States, Australia, France and more
- Nov 22, 2023Rigel Pharmaceuticals's first study: phase 2 study in GliomaNew to Rigel PharmaceuticalsRigel Pharmaceuticals · NCT06161974 · 60 planned · United States, Australia, Canada and more
- Mar 12, 2026Phase 4 study in Leukemia, Myeloid, AcuteRigel Pharmaceuticals · NCT07486713 · 16 planned · United States
- May 18, 2026Kissei Pharmaceutical's first study: phase 2 study in RecurrenceNew to Kissei PharmaceuticalKissei Pharmaceutical · NCT07604064 · 3 planned · Japan
Ahead
- Apr 30, 2027Primary completion: phase 4 study in Leukemia, Myeloid, AcuteRigel Pharmaceuticals · NCT07486713
- Jun 2029Primary completion: phase 2 study in GliomaRigel Pharmaceuticals · NCT06161974
- Sep 2030Primary completion: phase 2 study in RecurrenceKissei Pharmaceutical · NCT07604064
TargetBeta
“An orally available inhibitor of isocitrate dehydrogenase type 1 (IDH1; IDH-1; IDH1 [NADP+] soluble) with a mutation at arginine (R) 132, IDH1(R132), ”NCIt, by rule
“Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor”ChEMBL 37, by rule
Other programs on IDH1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ivosidenibrule | Agios Pharmaceuticals | phase 3 | 13 |
| vorasidenibrule | Agios Pharmaceuticals | phase 3 | 12 |
| ranosidenibrule | HUTCHMED | phase 3 | 7 |
| safusidenibrule | Nuvation Bio | phase 3 | 6 |
| IDH1 Inhibitor TQB3454 | Sino Biopharmaceutical | phase 3 | 5 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07604064Recurrence · Japan | 2 | Recruiting | Kissei Pharmaceutical | Sep 2030 | 3 |
| NCT07486713Leukemia, Myeloid, Acute · United States | 4 | Recruiting | Rigel Pharmaceuticals | Apr 30, 2027 | 16 |
| NCT06161974Glioma · United States, Australia, Canada and more | 2 | Recruiting | Rigel Pharmaceuticals | Jun 2029 | 60 |
| NCT03684811Glioblastoma · United States, Australia, France and more | 2 | Completed | Novo Nordisk | May 24, 2021 | 93 |
| NCT02719574Leukemia, Myeloid, Acute · United States, Australia, Canada and more | 2 | Completed | Novo Nordisk | Dec 28, 2023 | 336 |
How it is read
Names in the registry
- “Olutasidenib”, 2 entries
- “Olutasidenib + TMZ”, 1 entry
- “FT-2102 (olutasidenib)”, 1 entry
- “FT-2102”, 1 entry
Conditions, from the studies’ own filings
- Leukemia, Myeloid, Acute, 2 studies
- Glioma, 1 study
- Glioblastoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.